重组人脑钠肽治疗充血性心力衰竭患者50例临床分析

The Clinical Analysis of Patients with Congestive Heart Failure Treated by Recombinant Human Brain Natriuretic Peptide

目的:探讨重组人脑钠肽(rh BNP)治疗充血性心力衰竭患者的临床疗效及其机制。方法:将2011年1月-2013年12月住院治疗的充血性心力衰竭患者100例随机分为研究组和对照组各50例,两组在常规治疗基础上分别应用rh BNP和硝普钠治疗,比较两组的临床效果。结果:住院期间研究组与对照组的住院时间、心功能无明显差异,但研究组非致死性心脑血管事件、病死率和不良反应发生率明显低于对照组(P<0.05)。结论:重组人脑钠肽治疗充血性心力衰竭有效、安全。

Objective：To explore the clinical effect and the mechanism of recombinant human brain natriuretic peptide（rh BNP） for patients with congestive heart failure. Methods：100 patients with congestive heart failure were randomly divided into research group（n =50） and control group（n =50） accepted treatment of rh BNP and sodium nitroprusside based on the conventional therapy from Jan 2011 to Dec 2013. The clinical effects were compared between the two groups. Results： Compared with the control group,the hospital stays and heart function were no significantly different in the research group, but the incidence of non-fatal cardiac and cerebral vessels,hospital mortality and adverse accident were significantly lower（P〈0.05）. Conclusion： It is an effective and safe agent that patients with congestive heart failure treated by rh BNP.